John Kirby Net Worth

The estimated Net Worth of John J. Kirby is at least $643 Mille dollars as of 17 December 2021. Mr. Kirby owns over 10,000 units of Idera Pharmaceuticals stock worth over $16,182 and over the last 6 years he sold IDRA stock worth over $21,003. In addition, he makes $605,649 as Chief Financial Officer e Senior Vice President at Idera Pharmaceuticals.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Kirby IDRA stock SEC Form 4 insiders trading

John has made over 5 trades of the Idera Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of IDRA stock worth $6,200 on 17 December 2021.

The largest trade he's ever made was buying 10,000 units of Idera Pharmaceuticals stock on 17 December 2021 worth over $6,200. On average, John trades about 1,408 units every 51 days since 2019. As of 17 December 2021 he still owns at least 37,632 units of Idera Pharmaceuticals stock.

You can see the complete history of Mr. Kirby stock trades at the bottom of the page.

John Kirby biography

John J. Kirby CPA serves as Chief Financial Officer, Senior Vice President of the Company. He joined the Company in 2015 as the Company’s Vice President of Accounting and has served as Vice President of Finance since July 2018. Prior to joining the Company, Mr. Kirby served as Assistant Controller at Endo Pharmaceuticals, Inc. from November 2014 to October 2015. From August 2012 to July 2014, Mr. Kirby served as Vice President, Chief Accounting Officer and Corporate Controller at ViroPharma Incorporated. Mr. Kirby began his career at KPMG, LLP and served as a Regional Audit Director at AstraZeneca Pharmaceuticals prior to joining ViroPharma Incorporated. Mr. Kirby received his Bachelor of Science in Accountancy from Villanova University and is a licensed certified public accountant in the Commonwealth of Pennsylvania.

What is the salary of John Kirby?

As the Chief Financial Officer e Senior Vice President of Idera Pharmaceuticals, the total compensation of John Kirby at Idera Pharmaceuticals is $605,649. There are 3 executives at Idera Pharmaceuticals getting paid more, with Vincent Milano having the highest compensation of $1,337,220.

How old is John Kirby?

John Kirby is 47, he's been the Chief Financial Officer e Senior Vice President of Idera Pharmaceuticals since 2019. There are 17 older and no younger executives at Idera Pharmaceuticals. The oldest executive at Idera Pharmaceuticals, Inc. is Dr. Sudhir Agrawal D.Phil., DPHIL, F.R.S.C., 67, who is the Scientific Advisor.

What's John Kirby's mailing address?

John's mailing address filed with the SEC is 505 Eagleview Blvd, Exton, PA 19341, USA.

Insiders trading at Idera Pharmaceuticals

Over the last 17 years, insiders at Idera Pharmaceuticals have traded over $20,746,904 worth of Idera Pharmaceuticals stock and bought 38,459,430 units worth $53,771,070 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp Baker Bro... e Invest Corp Pillar Pharmace.... On average, Idera Pharmaceuticals executives and independent directors trade stock every 43 days with the average trade being worth of $309,429. The most recent stock trade was executed by John J. Kirby on 17 December 2021, trading 10,000 units of IDRA stock currently worth $6,200.

What does Idera Pharmaceuticals do?

Harnessing the approach of the earliest researchers in immunotherapy and the company's vast experience in developing proprietary immunology platforms, Idera's development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs.

Complete history of Mr. Kirby stock trades at Idera Pharmaceuticals

Idera Pharmaceuticals executives and stock owners

Idera Pharmaceuticals executives and other stock owners filed with the SEC include:

• Vincent Milano,
  President, Chief Executive Officer, Director
• Robert Fletcher,
  Senior Vice President - Business Development and Strategic Planning
• Bryant Lim,
  Senior Vice President, General Counsel, Corporate Secretary
• John Kirby,
  Chief Financial Officer, Senior Vice President
• Bryant David Lim,
  Sr. VP, Gen. Counsel & Corp. Sec.
• John J. Kirby,
  Sr. VP & CFO
• Vincent J. Milano,
  Pres, CEO & Director
• james Geraghty,
  Independent Chairman of the Board
• Carol Schafer,
  Independent Director
• Maxine Gowen,
  Independent Director
• Mark Goldberg,
  Independent Director
• Michael Dougherty,
  Independent Director
• Cristina Csimma,
  Independent Director
• Elizabeth Tarka,
  Senior Vice President, Chief Medical Officer
• Louis J. Arcudi III, M.B.A., MBA,
  Adviser
• Dr. Sudhir Agrawal D.Phil., DPHIL, F.R.S.C.,
  Scientific Advisor
• Dr. Sudhir Agrawal,
  Scientific Advisor
• Dr. Joanna C. Horobin Ch.B, M.B.,
  Advisor
• Dr. Shah Rahimian M.D., Ph.D.,
  Medical Director & Global Clinical Lead for Oncology
• Elizabeth Eberhardt,
  Sr. VP of Product Leadership
• Jill Conwell,
  Sr. VP of Investor Relations & Corp. Communications
• Daniel B. Soland,
  Sr. VP & COO
• Bros. Advisors Lp667, L.P.B...,
  
• William S Reardon,
  Director
• Invest Corp Pillar Pharmace...,
  
• Iii Louis J Arcudi,
  Chief Financial Officer
• Julianbaker Bros. Advisors ...,
  
• Invest Corp Pillar Pharmace...,
  
• Bros. Advisors Lp Baker Bro...,
  
• Invest Corp Pillar Pharmace...,
  
• Mark J Casey,
  Senior VP and General Counsel
• Julian Baker Bros. Advisors...,
  
• Youssef El Zein,
  Director
• Bros. Advisors Lp Baker Bro...,
  
• Alice Bexon,
  V.P. Clinical Development
• Alison Taunton Rigby,
  Director
• Sudhir Agrawal,
  CEO & CSO
• Invest Corp Pillar Pharmace...,
  
• Bros. Advisors Lp14159, L.P...,
  
• Invest Corp Pillar Pharmace...,
  
• Invest Corp Pillar Pharmace...,
  
• Jonathan Michael Yingling,
  Chief Scientific Officer
• Invest Corp Pillar Pharmace...,
  
• Invest Corp Pillar Pharmace...,
  
• Howard H Pien,
  Director
• Invest Corp Pillar,
  10% owner
• Paul C Zamecnik,
  
• Joanna Horobin,
  SVP and Chief Medical Officer
• Eve Elizabeth Slater,
  Director
• Malcolm Mac Coss,
  Director
• Timothy M Sullivan,
  VP Development Programs
• Umari Abdul Wahab,
  Director
• Louis Md Brenner,
  Chief Medical Officer
• Robert D. Arbeit,
  VP Clinical Development
• Robert W Karr,
  Director
• Pharmaceuticals I Lpzein Yo...,
  
• John Peter Iii Wolf,
  General Counsel
• Invest Corp Pillar Pharmace...,
  
• C Keith Hartley,
  Director
• Investment Group Lp Senator,
  10% owner
• Invest Corp Zein Youssef El...,
  
• Hans Mueller,
  Director
• James B Wyngaarden,
  Director
• Invest Corp Pillar Pharmace...,
  
• Invest Corp Pillar Partners...,
  
• Invest Corp Pillar Partners...,
  
• Daniel B Soland,
  CHIEF OPERATING OFFICER
• John Clayton Taylor,
  Chief Executive Officer
• Ronald J Wooten,
  Director
• Carl N Kraus,
  Chief Medical Officer
• Daniel Salain,
  Chief Operating Officer
• Co Investment Fund Xv, L.P....,